Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge
NCT ID: NCT01657097
Last Updated: 2012-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
24 participants
INTERVENTIONAL
1997-02-28
1997-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study was randomised, placebo-controlled double-blind in patients, monoallergic to grasspollen, presenting symptoms of rhinitis and asthma during season.
Treatment,ie intranasal corticosteroid or placebo, were given four weeks. After two weeks of treatment intranasal allergen challenge was performed. Measurements were performed during the full study period.
The study was performed out of pollen season.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INCS
Fluticasone propionate 400 microgram daily
INCS
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INCS
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* symptoms of allergic rhinitis for at least the two most recent grasspollen seasons
* asthma symptoms of asthma for at least two of the four most recent grasspollen seasons
* age 18 or older
Exclusion Criteria
* fertile women, not sterilised or using sufficient anticonception
* Corticosteroid treatment (parenteral, oral, inhaled or intranasal) within two months prior to enrolment
* Any other disease, condition or treatment, which to the discretion of the investigator has the potential to interfere with study results
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Dahl, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Respiratory Diseases, Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Respiratory Diseases, Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RHINO97
Identifier Type: -
Identifier Source: org_study_id